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Strengths and limitations of this study
 ► This is a community- based study focussing on older 
people with memory problems and diabetes.
 ► We used a mixed- methods approach exploring both 
participants’ and carers’ experiences using a contin-
uous glucose monitoring (CGM) device.
 ► Feasibility criteria included recruitment and reten-
tion, data capture with the CGM device, in addition 
acceptability of the device.
 ► The study monitoring period was only 2 weeks, 
which does not fully reflect longer term use of the 
device.
 ► The CGM device used in this study is known to have 
less accuracy at extremes of glucose values.
AbStrACt
Objectives Older people with diabetes are at increased 
risk of harm from hypoglycaemia, particularly where there 
are coexisting memory problems. Continuous glucose 
monitoring (CGM) offers important benefits in terms of 
detecting hypoglycaemia, but the feasibility of use and 
extent of data capture has not been tested in this patient 
group. Our objective was to investigate the feasibility of 
trialling a CGM intervention in the community setting in 
older people with diabetes and memory problems.
Design Mixed- methods feasibility study.
Setting Community dwellings in the UK.
Participants Patients aged ≥65 with diabetes and 
abbreviated mental test score ≤8 or known dementia.
Intervention FreeStyle Libre CGM.
Primary and secondary outcome measures Feasibility 
criteria were numbers of eligible patients, recruitment, 
attrition, extent of capture of glucose readings and adverse 
events. Qualitative interview.
results We identified 49 eligible participants; 17 
consented, but 5 withdrew before recording of data 
because they or their carers felt unable to manage 
study procedures. 12 participants (mean age 85 years) 
completed the study without adverse events. Data capture 
across 14 days ranged between 3% and 92% (mean 55%); 
6 participants had <60% capture. Hypoglycaemic events 
were recorded in six out of nine insulin users. Qualitative 
interviews found: the device does not interfere with daily 
activities, usability and comfort was positive, and it was 
helpful for carers in monitoring participants’ glucose 
concentrations.
Conclusions The device was acceptable to participants, 
and carers reported greater ease in monitoring 
the participant’s glucose concentrations. However, 
completeness of data capture varied considerably with this 
device due to the need for users to conduct ≥3 scans per 
day. Real- time devices with automated data transfer may 
be more suitable in older people with memory problems.
IntrODuCtIOn
It is estimated that 13%–20% of older 
people with dementia also have coexisting 
diabetes.1 Over the coming decades, this 
will pose a significant healthcare burden, 
especially in a worldwide expectation that by 
2045, 629 million people with be living with 
diabetes2 and 125 million people will be living 
with dementia by 2050.3
Self- management of diabetes is particu-
larly challenging for older patients, because 
they may have limited recall of the dangers 
of hypoglycaemia and what remedial action 
to take,4 and because they are more prone 
to hypoglycaemia from their medication.5 6 
Evidence from a recent meta- analysis reports 
that patients with diabetes and dementia may 
be even more susceptible to hypoglycaemia 
and subsequent cognitive complications.7 A 
cohort study using registry data from German 
and Austrian diabetes centres found that 
older people with diabetes and coexisting 
dementia had higher rates of severe hypo-
glycaemia (requiring third party assistance) 
and hypoglycaemia with coma compared 
with patients without dementia.8 Hence, the 
adverse effects of hypoglycaemia may be of far 
more pressing concern to frail older people, 
rather than strict glycaemic targets for reduc-
tion of vascular complications.
In this vulnerable group, the healthcare 
system should consider different approaches 
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for the monitoring of day to day glucose readings. 
Conventional methods, such as self- monitoring of 
blood glucose (SMBG), may not be appropriate in 
older people with memory problems, as they may not be 
able to recognise symptoms of changing blood sugars. 
Nocturnal and asymptomatic hypoglycaemia events are 
not reliably captured because SMBG only provides a 
snap shot of the glucose level at a single point in time 
where the user or carer has taken action to do finger- 
prick testing.
Newer technologies, such as continuous glucose moni-
toring (CGM), have gained momentum in the manage-
ment of diabetes, in particular in children and younger 
adults. This is now accompanied by a rapidly growing 
interest towards research studies of CGM in older people. 
A systematic review of studies using CGM in older people 
found that hypoglycaemic episodes were occurring in 
28%–65% of participants with most of those episodes 
(80%) being asymptomatic. Some participants spent 
up to 2 hours per day in the hypoglycaemic range. The 
review reported that older people found CGM use to 
be acceptable, with potential improvements in health- 
related well- being.9
However, to date we are not aware of studies that have 
explored the views and experiences of both the partici-
pants and their carers regarding the use of CGM in older 
people with diabetes and coexisting memory problems. 
Hence, our objective was to investigate the feasibility of 
using flash- glucose monitoring (a version of CGM) in this 
patient group. Specifically, we investigated recruitment, 
retention and the extent to which we could capture 
glucose data. In addition, we asked participants (and 
their carers) about their experience of using of the device 
(including anxiety or inconvenience related to wearing 
the CGM sensor) and whether they experienced any 
adverse events (pain or skin reactions).
MethODS
 Design
We used mixed methods to conduct a feasibility study 
of CGM in older people with diabetes and coexisting 
memory problems living in the community.
 Setting
Data collection took place in the community and the 
device was only fitted after patients had been discharged 
from acute care. The participants were initially identi-
fied and recruited while an inpatient under the Older 
People’s Medicine and/or Acute Medicine Departments 
at a University Hospital Trust in Norfolk, UK. We subse-
quently contacted the patients by telephone after their 
discharge from hospital to confirm their willingness to 
have the device fitted at their place of residence. Recruit-
ment took place between 1 February 2018 and 31 January 
2019.
 Sample size
This feasibility study aimed to estimate the important 
parameters for the sample size calculation for a full trial; 
no sample size calculation has been undertaken at this 
stage. We aimed to recruit up to 20 participants. This is 
a size that the research team considered to be pragmatic 
and sufficient as indicative quantitative data on which to 
base the sample size for a full trial.
 Choice of device
At commencement of this feasibility study, the CGM 
device (FreeStyle Libre) was licensed for use in chil-
dren and adults and available direct to consumers via 
the internet or from pharmacies. The use of this device 
provides ambulatory glucose profiles, giving graphic and 
quantitative information on 24- hour glucose patterns. 
This information can be viewed on a computer using the 
manufacturer’s software. It does not require finger- prick 
testing for calibration.
The system consists of a reader (although Android 
phones and certain ioS devices can download an app, 
which replaces the need for a reader) and a sensor (35 
mm × 5 mm), which exchange data through Near Field 
Communication technology. The sensor is applied to the 
back of a person’s arm. It is able to store blocks of glucose 
data spanning 8 hours and will function for 14 days. While 
glucose levels are measured continuously, data are not 
transmitted continuously from the sensor. Instead, the 
user has to swipe the sensor with a reader (hence the term 
‘flash glucose monitoring’ used by the manufacturer) at 
8 hourly intervals in order to achieve complete capture of 
data throughout the 2- week life- span of a sensor. If there 
is a gap of more than 8 hours between scans, then there 
will be missing data. For example, if there is a 10- hour gap 
between two scans, then there will be 2 hours of lost data.
The manufacturer of the device was not involved in the 
funding, the design or the interpretation of the study.
 Participants
Eligible participants were 65 or older with type 1 or type 2 
diabetes mellitus. They needed to be on glucose- lowering 
medication (not diet or Metformin only), have an abbre-
viated Mini- Mental Test (AMT) score equal or less than 
8 (out of 10)10 or already have a formal diagnosis of 
dementia. Use of the AMT is mandated as a screening 
tool for memory problems in the hospital policy.
The value of AMT in hospital settings was confirmed 
in a systematic review and meta- analysis on screening for 
dementia in general hospital inpatients, where AMT was 
reported to have good discriminant ability Area Under 
the Curve (AUC) 0.88.11
 Measurements
Feasibility outcomes (quantitative)
We investigated eligibility, recruitment, retention, reasons 
for withdrawal, data capture and adverse events. For cate-
gorical variables, the number and percentage will be 
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Figure 1 Patient recruitment flowchart.
Table 1 Baseline characteristics and data captured with FreeStyle Libre
1 2 3 4 5 6 7 8 9 10 11 12
Age 90 79 82 80 86 87 84 92 84 81 90 90
Type of diabetes 2 2 2 1 2 2 2 2 2 2 2 2
Insulin user, Y/N Y Y Y Y N N Y Y Y N Y Y
Daily finger- prick testing Y Y Y Y N N Y Y Y N Y Y
AMT, n/10 5 – 8 8 8 7 7 7 8 – – 7
Dementia, Y/N N Y N N N N N N N Y Y N
Days sensor worn 14 14 14 14 14 14 14 14 14 14 14 14
Data capture, % 70 62 65 83 38 3 34 76 92 33 55 43
Scans over 14 days 57 45 34 166 27 4 24 75 183 22 40 182
Average glucose, mmol/L 16.8 8.8 8.4 11.9 10.8 9.6 12.2 7.3 6.6 16.0 6.6 10.4
Hypo events (<4 mmol/L) – – 1 11 – – – 13 21 – 4 1
Average duration of low glucose events, 
min
    109 113       106 182   437 348
AMT, abbreviated Mini- Mental Test.
presented. For continuous variables, the mean or median 
will be presented.
For measure of ‘time in range’, we set the reader to 
record it between 4 mmol/L to 10 mmol/L, which is 
similar to expert recommendations.12 13
Participants were asked to continue with their usual 
diabetes management during the study period.
Patient outcomes (qualitative)
Semistructured face- to- face interviews took place after 
the participants had worn the device for 2 weeks. A topic 
guide was used (see online supplementary appendix 1) to 
ensure the same domains were covered in each interview. 
Participants and carers were encouraged to talk about 
their experiences using the device. Domains covered in 
the interview were acceptability of the device, explora-
tion of expectations, effectiveness, including experience 
of scanning the device and immediate or longer- term 
consequences for the user and their diabetes manage-
ment, consequences, including impact on wider health 
and well- being and overall opinion of the device. Detailed 
field notes were produced after each interview.
Thematic analysis was used, once the interviews had 
been transcribed.14 Familiarisation took place by listening 
to the interview recordings and reading of the transcripts.
Framework analysis was applied to order, chart and 
search the data manually and with software (NVivo 12, 
MS Word). To ensure rigour and trustworthiness, coding 
was undertaken by two members of the research team 
(KM and KL) and transcripts were checked for accuracy.
reSultS
The patient recruitment flowchart is set out in figure 1.
We identified 49 eligible participants. Seventeen people 
consented and 12 completed the study. During the inpa-
tient stay, information sheets were left at the bedside when 
it was not possible to speak to potential consultees (in 
cases where a patient did not have capacity) or a potential 
participant did not to discuss the study at the time of visit, 
but wanted to read the information sheet.
The main reason for deciding not to participate after 
discharge home was that the participant or carer felt it 
was too much to take on. Participants living on their own 
were finding it challenging coping with day to day life. 
Carers felt overwhelmed by the challenges of looking 
after the participant.
Table 1 sets out baseline characteristics and data 
captured with the FreeStyle Libre device for participants 
who completed the study period. Twelve participants 
(mean age 85 years) completed the study without any 
adverse events (skin reactions and/or pain). All had type 
2 diabetes apart form one participant with type 1 diabetes. 
Three participants had a formal diagnosis of dementia. 
The AMT for the nine participants who did not have a 
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Figure 2 Time in range for each participant.
Table 2 Care arrangements of participants who completed 
the study period
ID Accommodation
Social situation at time of 
interview
01 Room in Nursing 
Home
Lives in nursing home, nurse 
present at interview
02 House Lives with spouse (present at 
interview); package of care four 
times per day
03 Bungalow Lives with spouse (present at 
interview who is main carer
04 Bungalow In community hospital; spouse 
present at interview
05 Cottage Lives alone, independent
06 Bungalow Lives alone, cleaner, supportive 
family
07 House Lives alone, daughter helps
08 House Lives alone, package of care 
three times per day
09 Bungalow Lives with spouse (present at 
interview) who is main carer
10 House Lives with spouse (present at 
interview) who is main carer
11 House Lives with spouse (present at 
interview) who is main carer
12 Room in Nursing 
Home
Nursing home
formal diagnosis of dementia ranged between 5 and 8 out 
of 10.
Data capture across 14 days ranged between 3% and 
92% (mean 55%); six participants had less than 60% 
capture. Nine participants were insulin users, of which 
six (66%) experienced hypoglycaemic events (some 
prolonged). The average duration of hypoglycaemic 
events ranged from 106 min to 437 min.
figure 2 depicts the time in range for each participant, 
including the proportions spent below and above the 
target range (4–10 mmol/L). Figure 2 shows those partic-
ipants with hypoglycaemic episodes first, followed by the 
six participants who did not experience hypoglycaemic 
episodes. The percentage of time spent in the hypogly-
caemic range is illustrated in red (below 4 mmol/L), time 
spent in range in green (4–10 mmol/L) and time spent 
above range is illustrated in yellow (above 10 mmol/L).
results from the interviews
All participants (and, where applicable, carers) agreed to 
take part in the semistructured interview. The 12 inter-
views all took place in the participants’ homes, apart 
from three. Two of those three were nursing home resi-
dents (IDs #01 and #12), and one participant (ID #04) 
was in a community hospital for rehabilitation during 
the study period. The demographics of the participants 
who completed the study period are set out in table 2. 
Analysis of the main findings is presented below under 
key domains including acceptability, expectations, effec-
tiveness and consequences. Representative data extracts 
are presented verbatim (table 3) with all participant and 
carer identifiers removed and replaced by the partici-
pants’ and carers’ IDs.
 Acceptability
Participants and carers overwhelmingly found using 
the device acceptable. Almost without exception partic-
ipants reported the device was so unobtrusive that they 
did not know or were not conscious of wearing the device 
throughout the 2 weeks and that it did not interfere with 
day- to- day activities (table 3). In addition, participants 
confirmed that they were not aware of the device at night 
when they were sleeping.
Many participants described what they considered 
advantageous about the device. The most common 
example given was the elimination of finger- pricking. 
Participant #07 described that their fingers got sore from 
doing finger prick tests.
 exploration of expectations
When asked about expectations they had about wearing 
the device, many participants stated that they had had 
none. Participants were also asked if any expectations 
had come to mind about what it meant for their diabetes: 
again, they replied they had none.
One participant revealed an altruistic motivation to his 
joining the study (see table 3). Carer #11 also exhibited 
altruistic motivations when describing their expectations 
of being on the study, explaining that the findings will be 
positive for other people.15
Other expectations showed an interest in contrib-
uting to science and a natural curiosity of being part of a 
research study (table 3). For another participant, joining 
the study meant that they had an opportunity to ‘join the 
21st century’ (participant #04).
A distinct perspective was provided by the carer #02—
they admitted wondering if this was ‘a scam or something’, 
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Table 3 Illustrative quotes
Theme Illustrative quotes
Acceptability ‘I don’t even know it’s on’ (ID #07);
‘Easy to take a reading’ and ‘it was silent and stayed in place’ (ID #10).
Exploration of 
expectations
‘What they do with it, they can do what they like with me’ (ID #01);
‘You’ve got to work with science and progress’ (ID#03);
‘I found out what it did and I thought, this is fantastic’ (Carer ID #02).
Effectiveness ‘Well it’s better than pricking your finger cos my fingers got like sore’ (ID #07).
Consequences ‘…when it was low and then when I then give him something, it had then gone up so I knew it was 
working, so I was happy, more than happy with it. Yes, I felt happy and I felt safer.’ (Carer ID #11);
‘I just think it like I say with the whole package of the Alzheimer’s and dementia he’s not always 
understanding and doesn’t want it done and will pull his hand away and you know sometimes it’s just 
all too much’ (Carer ID #02).
Overall opinion ‘I’d tell them that it does away with the needle’ (ID#03);
‘We both think it’s progress and it’s going to help people in the future’ (Carer #03);
‘I’d do it (take part) again because it had been a positive experience’ (ID #05);
‘I really can’t see any (drawbacks), apart from the price I can’t think of any drawbacks’ (Carer ID #02).
but became reassured on hearing details about the device 
and the feasibility study (table 3).
 effectiveness
Interviews explored the experience of participants/carers 
using the device for 2 weeks and whether they felt they 
found any effectiveness for the user and their diabetes 
health. Participants/carers found using the device effec-
tive, some preferring it over SMBG.
Carers spoke favourably about the simplicity of the 
device, being ‘handy at night- times’ (carer #02) for 
checking glucose levels without disturbing the partici-
pant and about the participant not being limited to the 
number of times they could check their glucose levels.
 Consequences
The impact on participants’ and carers’ wider health and 
well- being was explored. In particular, we were interested 
whether they found any aspects of the experience posi-
tive or negative. This included their views on whether the 
device had an impact on their symptoms, their experi-
ences of living with diabetes and coexisting memory prob-
lems and on their socialising and day- to- day activities.
Although no participant reported anxiety or stress in 
wearing the device, a few reported that they wondered 
about the different results obtained from the device 
compared with finger- pricking. Participant ID#12 
expressed disappointment that the readings from the 
device did not always match the readings from the finger 
prick test.
Carers found the device particularly useful as it made 
them feel reassured and safer being able to check glucose 
levels, without having to use SMBG. No reports of anxiety 
or stress in using the device were given by carers (table 3).
Another carer made the point of participant #02 not 
always understanding the need for SMBG due to the 
underlying dementia (table 3).
One participant reported that wearing the device ‘made 
them feel confident’ and, now that the 2- week episode 
had ended, they would ‘miss it … it was a boon to have it’ 
(participant #013).
 Overall
Participants were asked if they would recommend the 
device to others or what would they would say about their 
attitude to device to anyone who was considering it. They 
all responded positively about recommending the device.
One drawback mentioned was financial (table 3). Some 
participants remarked on discrepant readings provided 
by the device compared with finger- pricking. One partic-
ipant was explicit that they would like the device ‘to be 
more accurate’, comparing its readings less favourably 
with finger- pricking the results of which, they said, set 
their mind ‘more at rest’ (participant #09). Nevertheless, 
the overall view of the device remained positive.
DISCuSSIOn
This study has shown that while the participants found 
wearing the sensor acceptable, data capture varied, 
depending on how many times the reader was used to 
scan the sensor during the study period. This is in contrast 
to findings from Ruedy et al’s study (a posthoc analysis of 
the multicentre DIAMOND trial) looking at the effective-
ness of CGM in adults aged 60 years and older with type1 
or type 2 diabetes using multiple daily insulin injections. 
The authors found that of the 61 participants in the CGM 
group completing the study, 97% used CGM six or more 
days per week at the 6- month follow- up.16
It should be noted though that these participants were 
not frail, and the inclusion criteria required a stable 
diabetes regime for 3 months prior to study entry, use of 
SMBG three or more times daily, with no history of recur-
rent hypoglycaemia.17
Our study illustrates the real- world difficulties that 
older people with memory problems and their carers 
face in glucose self- monitoring. We are aware of other 
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studies using flash glucose monitoring in older people, 
but these have not reported on the extent of data 
capture.18 19
Future studies should employ a CGM device that 
does not require participants to carry out an action (eg, 
swiping reader over sensor), in order to transfer data and 
obtain a reading. Nevertheless, some carers found it to 
be a useful and reassuring tool in managing this complex 
group of patients without having to resort to finger prick 
testing in a person who may not be able to understand the 
reasons for it.
Based on a recently published international consensus 
on clinical targets for CGM data interpretation, only 4 out 
of the 12 participants reached the target of 70% or more 
data capture in fourteen days.13 The consensus statement 
for CGM targets in older people is that they should spend 
more than 50% in the target range (3.9–10 mmol/L), 
less than 1% below the target range (<3.9 mmol/L) and 
less than 10% above target (>13.9 mmol/L). Of the six 
participants who experienced hypoglycaemic episodes 
during the 14 days of wearing the device, only one spent 
1% below the target range. Six participants reached the 
above 50% time in range target.
Recruitment proved challenging in this vulnerable 
group, particularly because we chose to identify and 
recruit potential participants while they were inpatients 
in an acute hospital setting. Challenges arose when a 
potential participant lacked capacity and consultee infor-
mation sheets were left with the patient. Often it was not 
possible to speak to next of kin, relatives or friends who 
could have been consultees, due to the unpredictability 
of visiting and some patients not being visited at all while 
in hospital. As a result, a group of potential participants 
did not get the opportunity to consider taking part in this 
study. In addition, it became apparent that on discharge 
some participants found getting back into a daily routine 
and coping with day- to- day life overwhelming and there-
fore decided to withdraw from the study, despite showing 
interest in principle.
Factors such as acute illness and the disorientating and 
stressful environment of being in hospital meant that 
potential participants were at times not in the best posi-
tion to digest lots of information about taking part in the 
study. Following on from this, it would be advisable to try 
and recruit in the community via primary care, but the 
initial approach is still challenging as traditional methods 
(eg, sending out letters of invitation with reply slips) may 
not succeed.
Regarding retention, it became apparent that on 
discharge some participants (or their carers) found getting 
back into a daily routine and coping with day- to- day life 
overwhelming and therefore decided to withdraw from 
the study, despite showing interest in principle. Greater 
trial support (eg, research nurses) for participants and 
carers may help address this.
Our feasibility study demonstrates that subsequent 
larger trials must address the above challenges, in order 
to maximise recruitment, retention and data capture.
 Strengths and limitations
Our study used a mixed- methods approach exploring 
participants’ and carers’ experiences during the study 
period.
With regard to the use of the AMT, we acknowledge 
that its use only covers three cognitive domains (memory, 
orientation, attention/calculation) and there are more 
rigorous cognitive tests available. The more rigorous tests 
do not necessarily lend themselves to being carried out 
in an acute busy hospital setting.20 Our feasibility study 
was not about making new dementia diagnoses. Rather, 
we wanted to identify inpatients with any memory prob-
lems (irrespective of the possible underlying pathology) 
during their hospital admission who might benefit from 
the use of CGM. We appreciate that differences in cogni-
tive profiles may arise according to type of diabetes or 
other underlying psychological issues, but this does not 
change the need for a strategy of hypoglycaemia detec-
tion and minimisation.
With regard to the capture of hypoglycaemia, the 
manufacturer of FreeStyle Libre has reported their 
sensor may have less accuracy in the lower glucose ranges 
when compared with SMBG. A clinical study showed that 
40% of the time when the device indicated an intersti-
tial glucose level of less than 3.3 mmol/L, the capillary 
reading was between 4.5 mmol/L and 8.9 mmol/L. A 
further study carried out in France with older patients 
with type 2 diabetes (on insulin) in care homes, found 
that 51% of hypoglycaemic episodes captured with Free-
Style Libre were associated with values equal or greater 
than 3.9 mmol/L on capillary readings.18
Despite limitations of the FreeStyle Libre in hypogly-
caemia capture, our findings are supported by two recent 
pieces of research. A conference abstract presented at 
Endo 201919 (New Orleans 23–26 March 2019) on the 
exposure to hypoglycaemia in older adults with type 1 
diabetes analysed blinded CGM (Dexcom G4 Platinum) 
data in over 200 older adults (median age 68 years) 
collected at baseline in a randomised controlled trial, 
assessing the effect of CGM on hypoglycaemia. These 
older adults spend over 1 hour per day in the hypogly-
caemic range and over 100 min per day in those with 
impaired hypoglycaemic awareness.19 In addition, a 2019 
Japanese study investigated the use of blinded CGM 
(Medtronic iPro2) in older people in an outpatient 
setting in Japan. Out of 326 participants, 7 used CGM. 
Asymptomatic hypoglycaemic episodes occurred in five 
out of the seven CGM users.21
While our feasibility study took place within one area of 
the UK, we believe that the results are potentially gener-
alisable to the rest of the older population in the UK with 
diabetes and memory problems. We believe that older 
people with memory problems anywhere in the world 
will face similar hurdles when using a new technolog-
ical device. However, we had difficulty recruiting eligible 
participants who had severe dementia needing full- time 
residential care. Our findings cannot be generalised to 
this group.
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 Meaning of findings and potential for future work
CGM has gained momentum in the last few years, with 
more affordable devices being freely available for people 
with diabetes to purchase. However, the focus has very 
much been on adults and children with type 1 diabetes 
and pregnant women. More recently, the National Health 
Service published its long- term plan, making reference to 
the fact that from April 2019, patients with type 1 diabetes 
benefit from flash glucose monitors ending the variation 
patients in some parts of the country are facing.22 While 
this is a very welcome development, there is a need to 
seriously think about older frail people (especially those 
on insulin and/or with memory problems) and how best 
to manage diabetes in later life focussing on avoidance of 
hypoglycaemia and its adverse effects. This will require 
an enormous shift in mindset by healthcare professionals 
and policy makers.
A key area for investigation is what type of CGM (ie, 
intermittent scanning/flash glucose monitoring, contin-
uous transmission via Bluetooth or blinded and retro-
spective CGM) would be most appropriate in this group 
of patients? Second, how often should CGM be employed 
(all the time, when there is a change in drugs or intermit-
tently for troubleshooting)? Third, should it be limited to 
insulin and sulfonylurea users, which carry a higher risk 
of hypoglycaemia? Finally, it would be important to iden-
tify facilitators and barriers to CGM use in older people 
with memory problems, with specific focus on factors 
such as dementia severity, functional status, availability of 
carers, familiarity with self- monitoring and so on that can 
influence data capture.
There is a clear need for a large- scale prospective 
study using CGM to assess its true potential impact in 
this vulnerable group. CGM would be used to capture 
hypoglycaemic episodes and guide the hypoglycaemia 
minimisation strategy. In addition, CGM may be a useful 
and supportive tool for carers in their day to day care of 
this vulnerable group of older people, especially those 
on insulin. Further work is needed to explore whether 
older people with memory problems will be able to deal 
with the technology for continuous Bluetooth capture 
and reacting to the data that is produced by the software, 
including alarms for high and low glucose levels.
COnCluSIOn AnD IMPlICAtIOnS
It is potentially feasible for older people with diabetes and 
memory problems to operate a CGM device that requires 
users to conduct intermittent scans. However, the added 
benefit of real- time transmission CGM devices that do not 
require active scanning needs to be explored further in 
this group of patients.
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